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Aims Conflicting results have been reported regarding the effect of beta-blockers on first-registered heart rhythm in
out-of-hospital cardiac arrest (OHCA). We aimed to establish whether the use of beta-blockers influences first-
registered rhythm in OHCA.
...................................................................................................................................................................................................
Methods
and results
We included patients with OHCA of presumed cardiac cause from two large independent OHCA-registries from
Denmark and the Netherlands. Beta-blocker use was defined as exposure to either non-selective beta-blockers,
b1-selective beta-blockers, or a-b-dual-receptor blockers within 90 days prior to OHCA. We calculated odds ra-
tios (ORs) for the association of beta-blockers with first-registered heart rhythm using multivariable logistic regres-
sion. We identified 23 834 OHCA-patients in Denmark and 1584 in the Netherlands: 7022 (29.5%) and 519
(32.8%) were treated with beta-blockers, respectively. Use of non-selective beta-blockers, but not b1-selective
blockers, was more often associated with non-shockable rhythm than no use of beta-blockers [Denmark: OR 1.93,
95% confidence interval (CI) 1.48–2.52; the Netherlands: OR 2.52, 95% CI 1.15–5.49]. Non-selective beta-blocker
use was associated with higher proportion of pulseless electrical activity (PEA) than of shockable rhythm (OR 2.38,
95% CI 1.01–5.65); the association with asystole was of similar magnitude, although not statistically significant com-
pared with shockable rhythm (OR 2.34, 95% CI 0.89–6.18; data on PEA and asystole were only available in the
Netherlands). Use of a-b-dual-receptor blockers was significantly associated with non-shockable rhythm in
Denmark (OR 1.21; 95% CI 1.03–1.42) and not significantly in the Netherlands (OR 1.37; 95% CI 0.61–3.07).
...................................................................................................................................................................................................
Conclusion Non-selective beta-blockers, but not b1-selective beta-blockers, are associated with non-shockable rhythm in
OHCA.
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Introduction
The incidence of shockable rhythm [ventricular tachycardia (VT),
ventricular fibrillation (VF)] as first-registered heart rhythm in out-of-
hospital cardiac arrest (OHCA) has exhibited an absolute and
relative decline worldwide compared with non-shockable rhythm
[pulseless electrical activity (PEA) and asystole] during the last deca-
des.1–3 Several causes for this decreased incidence have been sug-
gested, such as decline in mortality from ischaemic heart disease
(IHD), increased use of implantable cardiac defibrillators, and
improvements in heart failure management,1 with beta-blockers as
cornerstone of the medical therapy.4 The chronic use of beta-
blockers has increased significantly during the last decades primarily
because of their favourable effects on mortality after myocardial in-
farction and in congestive heart failure (CHF).5 This increase has
been suggested as one of the contributing factors for the decline of
shockable rhythm in OHCA, considering the antifibrillatory and anti-
arrhythmic properties of these drugs.2 Previous studies have shown
that beta-blocker use may influence first-registered heart rhythm, but
these studies have yielded conflicting results.6–9 Given the impor-
tance of the first-registered heart rhythm in post-resuscitation treat-
ment and prognosis,10 we aimed to clarify this controversy by
analysing real-world data from two large independent population-
based OHCA-registries from Denmark and the Netherlands. We
studied whether use of beta-blockers at the time of OHCA influ-
enced the first-registered heart rhythm in OHCA (shockable vs. non-
shockable). We distinguished between use of non-selective beta-
blockers, b1-selective beta-blockers, and a-b-dual-receptor blockers,
because these drug classes impact differently on various relevant car-
diac and extracardiac functional properties.
Methods
Data availability
The data and study materials are not available to other researchers for
purposes of reproducing the results or replicating the procedure.
Study design and setting
We performed a population-based cohort study using data from two
large ongoing Emergency Medical Services (EMS) attended OHCA-
registries in Denmark and the Netherlands. Both registries are part of the
ESCAPE-NET project that aims to study the causes and to develop effec-
tive treatments for OHCA across 10 European countries.11 From both
cohorts, we included adult patients with OHCA of presumed cardiac
cause (Figure 1). We excluded patients with (i) unknown first-registered
heart rhythm, (ii) presumed non-cardiac cause of OHCA (e.g. drowning,
trauma, asphyxia), (iii) missing estimated time interval from recognition of
OHCA to rhythm analysis by EMS, (iv) estimated time of arrival by EMS
>_30 min, or (v) incomplete drug dispensing records (this last condition
only applied to the Dutch registry). This study was conducted according
to the principles described in the Declaration of Helsinki and was ap-
proved by the Ethical Committee of the Academic Medical Center,
Amsterdam, and the Danish Data Protection Agency (2007-58-0015, in-
ternal reference GEH-2014-017, I-Suite No. 02,735). In Denmark, ethical
approval is not required for observational, registry-based studies where
patients remain anonymous.
Denmark
The population-based Danish Cardiac Arrest Register (DANCAR)
includes all OHCAs across Denmark for which EMS were dispatched and
where resuscitation efforts, either by a bystander or EMS personnel, have
been attempted (2001–2014). The EMS is activated for all medical emer-
gencies in Denmark, and EMS-personnel is required to fill out a case re-
port form for every OHCA: the first-registered heart rhythm is reported
in such case reports as a binary variable (non-shockable or shockable
rhythm). The causes of OHCA were extrapolated from the death certifi-
cates and discharge diagnoses from the index hospitalization. When the
cause of the underlying OHCA was cardiac disease, unknown disease, or
unexpected collapse, the arrest was classified as of presumed cardiac
cause. DANCAR has been described in detail elsewhere.12 All residents in
Denmark have a unique and permanent personal civil registration number
that allows individual-level linkage across nationwide registries. All admis-
sions to Danish hospitals are registered since 1978 in the Danish National
Patient Registry: diagnoses are classified according to the International
Classification of Diseases (ICD). The National Prescription Register contains
information on all dispensed drug prescriptions since 1995, classified
according to the Anatomical Therapeutic Chemical (ATC) system. The
Danish Civil Registration System provides data about patient’s age and
gender; the Danish Register of Causes of Death holds information about
vital status and causes of death, including primary and contributing causes.
The Netherlands
The population-based AmsteRdam REsuscitation STudies (ARREST) reg-
istry is an ongoing observational study that prospectively includes all
OHCAs in one contiguous region of the Netherlands (North Holland
province). This study region has a population of 2.6 million and covers
2404 km2, both rural and urban areas. A detailed description of ARREST
is provided elsewhere.13 In short, the ARREST study centre is notified by
the dispatch centre when there is a suspected OHCA in which EMS is in-
volved. Electrocardiograms from EMS manual defibrillator or automated
external defibrillation, whichever defibrillated first, were obtained to es-
tablish the first-registered heart rhythm. The first-registered heart
rhythm was categorized as shockable (VT, VF) or non-shockable (asys-
tole, PEA). For this study, data from 2009 to 2012 was used. To establish
medication use, drug dispensing records 1 year prior to OHCA were
obtained by contacting the patient’s community pharmacy. These
records were considered complete, since nearly all patients in the
Netherlands are registered at a single community pharmacy. Medical
What’s new?
• The use of beta-blockers prior to out-of-hospital cardiac
(OHCA) arrest may influence the first-registered heart
rhythm.
• The different classes of beta-blockers have different effects on
the first-registered heart rhythm in OHCA.
• The use of non-selective beta-blockers is associated with non-
shockable heart rhythm in OHCA, particularly with pulseless
electrical activity.
• The use of b1-selective beta-blockers is not associated with
non-shockable heart rhythm in OHCA.
• When we considered differences in baseline comorbidities,
the use of non-selective beta-blockers persisted associated
with non-shockable heart rhythm.
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history was obtained by contacting the hospital of admission and the
general practitioner (GP). The GPs were asked to fill out a questionnaire
to identify whether patients were diagnosed with any medical condition
before their OHCA. Also, GP records contain information on hospital
admissions and related diagnoses.13
Exposure of interest
Beta-blocker use was defined as starting in (ARREST) or covering
(DANCAR) a period of maximum 90 days prior to OHCA (see
Supplementary material online, Table S1 for ATC codes). In DANCAR,
the treatment duration was calculated by dividing the number of tablets
from the prescription of interest by daily dosage. We determined the
daily dosage estimating the mean dosage from up to five consecutive pre-
scriptions before the prescription of interest.14 If more than one beta-
blocker was prescribed within 90 days prior to OHCA, beta-blocker use
was defined according to the most recent prescription. Moreover, in
DANCAR, we stratified analyses according to the daily dosage (low/high)
of beta-blockers (see Supplementary material online, Table S1 for the
classification of doses).
Similarly, we examined the association between angiotensin-
converting enzyme (ACE) inhibitors, which have similar indications as
beta-blockers, and first-registered heart rhythm to assess possible con-
founding by indication (see Supplementary material online, Table S2 for
ATC codes).
Covariates
We identified baseline comorbidity up to 10 years before OHCA from
the Danish National Patient Register (complete ICD codes are provided
in Supplementary material online, Table S3). In ARREST, the same comor-
bidities were identified by contacting the hospital of admission and the
GP. Also, use of medications with potential effects on first-registered
heart rhythm was evaluated.9 Use of these medications were defined as
having a drug dispensing record up to 180 days prior to OHCA. (ATC-
codes are provided in Supplementary material online, Table S4).
Statistical analysis
In both cohorts, the association between beta-blocker use and first-
registered heart rhythm was studied using logistic regression analysis.
Furthermore, in ARREST, we studied the association between beta-
blocker use and specific first-registered heart rhythm—distinguishing be-
tween PEA and asystole—by multinomial logistic regression analysis using
complete cases. We calculated both crude estimates (unadjusted analy-
sis) and multivariable analysis adjusted for age, sex, OHCA-related
parameters [location of OHCA, presence/absence of bystander cardio-
pulmonary resuscitation (CPR) or EMS-witnessed OHCA, and time from
recognition of OHCA to EMS arrival], year of OHCA (only in DANCAR,
because in ARREST we could only include OHCAs from 2009 to 2012)
and all comorbidities and medications listed in Table 1. Analyses were
conducted for the overall use of any beta-blocker (reference: no use of
any beta-blocker), and separately for different classes of beta-blockers
(reference: no use of any beta-blocker). Subgroup analysis was per-
formed (i) among witnessed OHCAs (bystander or EMS witnessed) with
estimated time to rhythm analysis <_10 min and (ii) in subsets of patients
classified by the presence of certain comorbidities at baseline: CHF, IHD,
atrial fibrillation (AF), hypertension, and individuals without cardiovascu-
lar disease (absence of IHD, CHF, AF, or use of digoxin or antiarrhythmic
drugs). Finally, we examined the association between ACE inhibitors and
first-registered heart rhythm. Results are presented as odds ratios (ORs)
with 95% confidence intervals (CIs). Categorical data are presented as ab-
solute numbers and percentages, and continuous data as mean and stan-
dard deviation or medians together with their associated quartiles.
Results
Patient characteristics
From DANCAR, we included 23 834 OHCA-patients (mean age
70.3, 68.4% male, Figure 1). Of these, 7022 (29.5%) used a beta-
blocker within 90 days before OHCA (Table 1), including 458 who
45 293 OHCA
2001-2014
23 834 patients included in the study 1584 patients included in the study
2513 OHCA
with complete medication use
2009-2012
36 unknown initial rhythm
759 non-cardiac causes
28 aged < 18;
106 time from emergency call to
first rhythm analysis > 30 min or
missing time
12 621 due to presumed non-cardiac
cause of OHCA
207 due to age < 18 or > 100
8074 due to time to ambulance arrival
>30 min or missing
557 due to missing initial rhythm
Any beta-blocker
519
No beta-blockers
1065
Non-selective
beta-blockers
458
b1-selective
beta-blockers
5432
a-b dual receprors
blockers
1132
a-b dual receprors
blockers
37
b1-selective
beta-blockers
439
Non-selective
beta-blockers
43
No beta-blockers
16 812
Any beta-blocker
7022
A B
Figure 1 Patient flow chart. (A) DANCAR registry. (B) ARREST registry. OHCA, out-of-hospital cardiac arrest.
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used non-selective beta-blockers, 5432 who used b1-selective beta-
blockers, and 1132 who used a-b-dual-receptor blockers (Table 2).
From ARREST, we included 1584 OHCA-patients (mean age 68.2,
72.2% male, Figure 1). Of these, 519 (32.8%) used a beta-blocker
within 90 days before OHCA (Table 1), including 43 who used non-
selective beta-blockers, 439 who used b1-selective beta-blockers,
and 37 who used a-b-dual-receptor blockers (Table 2).
Beta-blocker use and first-registered
heart rhythm
In DANCAR, the overall use of beta-blockers was associated
with increased odds of non-shockable rhythm [ORadj 1.16 (1.07–
1.26), Figure 2] compared with no use of any beta-blocker. We
found a significant association between non-shockable rhythm and
use of non-selective beta-blockers [ORadj 1.93 (1.48–2.52)] or a-
.................................................................. ...............................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of subjects with out-of-hospital cardiac arrest stratified into beta-blocker users and
non-users
DANCAR ARREST
Any
beta-blocker
No
beta-blockers
Missing
data
Any
beta-blocker
No
beta-blockers
Missing
data
Total 7022 (29.5) 16 812 (70.5) 519 (32.8) 1065 (67.2)
Age (years), mean (SD) 72.7 (11.7) 69.2 (14.2) NA 72.43 (10.9) 66.17 (14.4) NA
Male sex 4845 (69.0) 11 447 (68.1) NA 371 (71.5) 773 (72.6) NA
Resuscitation factors
OHCA in private home 4644 (74.2) 10 161 (69.3) 2920 (12.2) 403 (77.6) 773 (72.7) 2 (0.1)
Witnessed status 3586 (51.2) 8550 (51.1)
Bystander-witnessed OHCA 1012 (14.5) 2389 (14.3) 106 (0.5) 337 (65.7) 704 (66.5) 12 (0.8)
EMS-witnessed OHCA 2397 (34.3) 5794 (34.6) 56 (10.9) 98 (9.3)
Unwitnessed OHCA 120 (23.4) 257 (24.3)
CPR status
Bystander CPR 2645 (37.7) 6328 (37.7) 57 (0.2) 332 (65.0) 722 (68.7) 22 (1.4)
EMS-witnessed OHCA 1012 (14.4) 2389 (14.3) 56 (10.9) 98 (9.3)
Neither bystander CPR nor EMS-witnessed OHCA 3352 (47.9) 8051 (48.0) 123 (24.1) 231 (22.0)
Median time from recognition of
OHCA to EMS arrival, min (IQR)a
9 (4–15) 9 (4–14) NA 8.2 (5.7–11.2) 8.1 (5.8–11.1) NA
Comorbidity
Ischaemic heart diseaseb 3704 (52.8) 2810 (16.7) NA 219 (43.0) 165 (16.2) 55 (3.5)
Congestive heart failure 2706 (38.5) 2059 (12.3) NA 195 (38.7) 129 (12.7) 67 (4.2)
Atrial fibrillation 2211 (31.5) 1830 (10.9) NA 147 (29.3) 123 (12.2) 70 (4.4)
Chronic obstructive pulmonary disease 1072 (15.3) 2286 (13.6) NA 83 (16.7) 147 (14.6) 77 (4.9)
Diabetes mellitus 1783 (25.4) 2359 (14.0) NA 167 (32.7) 173 (16.7) 51 (3.2)
Cerebrovascular disease 1239 (17.6) 2004 (11.9) NA 94 (18.8) 115 (11.4) 78 (4.9)
Hypertension 2155 (30.7) 2363 (14.1) NA 334 (65.5) 421 (41.3) 55 (3.5)
Dyslipidaemia 3354 (47.8) 3093 (18.4) NA 217 (42.7) 275 (27.0) 58 (3.7)
Chronic kidney disease 802 (11.4) 684 (4.1) NA 98 (19.8) 71 (7.1) 89 (5.6)
Liver disease 131 (1.9) 353 (2.1) NA 19 (3.8) 30 (3.0) 89 (5.6)
Concomitant medication
Antipsychotics 394 (5.6) 1334 (7.9) NA 14 (2.7) 32 (3.0) NA
Antidepressants 1356 (19.3) 2873 (17.1) NA 33 (6.4) 64 (6.0) NA
Anxiolytics/hypnotics 1831 (26.1) 3550 (21.1) NA 102 (19.7) 134 (12.6) NA
Corticosteroids 759 (10.8) 1753 (10.4) NA 35 (6.7) 73 (6.9) NA
Digoxin 1411 (20.1) 1571 (9.4) NA 59 (11.4) 36 (3.4) NA
Antiarrhythmic drugs, Class I and III 287 (4.1) 184 (1.1) NA 27 (5.2) 18 (1.7) NA
Numbers are number (%) unless indicated otherwise.
Note: In the calculation of percentages, observations with missing value for the covariate involved in calculation were excluded.
CPR, cardiopulmonary resuscitation; EMS, emergency medical system; IQR, interquartile range; NA, not applicable; OHCA; out-of-hospital cardiac arrest; SD, standard
deviation.
aEMS-witnessed excluded.
bAcute myocardial infarction included.
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b-dual-receptor blockers [ORadj 1.21 (1.03–1.42)], but not b1-se-
lective beta-blockers [ORadj 1.04 (0.95–1.13)]. In ARREST, the
overall use of beta-blockers was not associated with increased
odds of non-shockable rhythm [ORadj 1.08 (0.82–1.42), Figure 2].
The other key findings in DANCAR were reproduced in
ARREST: increased odds of non-shockable rhythm was associated
with use of non-selective beta-blockers [ORadj 2.52 (1.15–5.49)],
but not b1-selective beta-blockers [ORadj 0.99 (0.74–1.31)]. Use
of a-b-dual-receptor blockers was not significantly associated
with non-shockable rhythm [ORadj 1.37 (0.61–3.07), Figure 2].
We also found that non-selective beta-blocker use was associated
with PEA [ORadj 2.38 (1.01–5.65)], but not asystole [ORadj 2.34
(0.89–6.18)] when compared with shockable rhythm (Figure 3).
Neither use of b1-selective beta-blockers nor a-b-dual-receptor
blockers was associated with PEA or asystole compared with
VT/VF (Figure 3). The results for the individual beta-blockers for
both registries are listed in the Supplementary material online,
Table S5.
When we stratified the analyses according to the dosage, we found
that only high dose of any beta-blocker, non-selective, and a-b-dual-
receptor blockers were associated with increased likelihood of non-
shockable rhythm (Supplementary material online, Figure S1).
DANCAR registryA
B
Number
of patients
No use of beta blockers
Use of any beta-blocker
Type of beta-blocker
Non-selective beta-blockers
b1-selective beta-blockers
a-b dual receptor blockers
No use of beta blockers
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Type of beta-blocker
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a-b dual receptor blockers
1065
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439
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561 (52.7%)
259 (49.9%)
14 (32.6%)
230 (52.4%)
15 (40.5%)
504 (47.3%)
260 (50.1%)
29 (67.4%)
209 (47.6%)
22 (59.5%)
1.00 [1.00–1.00]
1.12 [0.91–1.38]
2.31 [1.21–4.41]
1.01 [0.81–1.26]
1.63 [0.84–3.18]
1.00 [1.00, 1.00]
1.08 [1.82, 1.42]
2.52 [1.15, 5.49]
0.99 [0.74, 1.31]
1.37 [0.61, 3.07]
16 812
7022
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5432
1132
5550 (33.0%)
2287 (32.6%)
85 (18.6%)
1798 (33.1%)
404 (35.7%)
11 262 (67.0%)
4735 (67.4%)
373 (81.4%)
3634 (66.9%)
728 64.3%)
1.00 [1.00–1.00]
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0.89 [0.78–1.01]
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0.5
Shockable Non-shockable
Shockable Non-shockable
Odds Ratio [95% CI]
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0.5
Odds Ratio [95% CI]
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Patients
with shockable rhythm
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with non-shockable rhythm
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Odds Ratio
Adjusted Odds Ratio
[95% CI]
Number
of patients
Patients
with shockable rhythm
Patients
with non-shockable rhythm
Unadjusted
Odds Ratio
Adjusted Odds Ratio
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ARREST registry
Figure 2 Use of beta-blockers and odds of first-registered heart rhythm being non-shockable. (A) DANCAR registry. (B) ARREST registry. CI, con-
fidence interval; DHP, dihydropyridine. Numbers in table are number (%) unless indicated otherwise. Error bars denote 95% confidence interval. The
results are adjusted for all the covariates listed in Table 1.
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Subgroup analysis—witnessed out-of-
hospital cardiac arrest with estimated
time to rhythm analysis 10 min
In both cohorts, the main results were confirmed by subgroup
analysis including only witnessed OHCAs (bystander or EMS wit-
nessed) with estimated time to rhythm analysis <_10 min: use of
non-selective beta-blockers was associated with increased odds of
non-shockable rhythm [DANCAR: ORadj 1.94 (1.33–2.83),
ARREST: ORadj 6.79 (2.25–20.50)], while use of b1-selective beta-
blockers or a-b-dual-receptor blockers was not (Supplementary
material online, Figure S2).
Subgroup analysis—baseline
comorbidity
In DANCAR, in subgroup analyses based on the presence of certain
comorbidities, use of non-selective beta-blockers was consistently
associated with higher odds of non-shockable rhythm compared with
no use of any beta-blocker, even among patients without cardiac co-
morbidity (Supplementary material online, Table S6). We found a sig-
nificant association between a-b-blockers and non-shockable heart
rhythm only among patients with IHD and in patients without cardiac
disease (Supplementary material online, Table S6). No association in
any subgroup was seen for b1-selective blockers. Subgroup analyses
Patients
with shockable rhythm
No use of beta blockers
Use of any beta-blocker
Type of beta-blocker
Non-selective beta-blockers
b1-selective beta-blockers
a-b dual receptor blockers
No use of beta blockers
Use of any beta-blocker
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561 (52.7%)
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14 (32.6%)
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107 (24.4%)
1.00 [1.00–1.00]
1.17 [0.91–1.52]
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1.07 [0.81–1.41]
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0.87 (0.62, 1.24)
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0.5 1.5
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Patients
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Patients
with shockable rhythm
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Patients
with asystole
Adjusted Odds Ratio
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A
B
Figure 3 Use of beta-blockers and odds of PEA vs. VT/VF and asystole vs. VT/VF. (A) PEA versus VT/VF. (B) Asystole vs. VT/VF, PEA vs. asystole.
Data on PEA and asystole only available in ARREST. Numbers in table are number (%) unless indicated otherwise. Error bars denote 95% confidence
interval. The results are adjusted for all the covariates listed in Table 1. CI, confidence interval; PEA, pulseless electrical activity; VT/VF, ventricular
tachycardia/ ventricular fibrillation.
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for ARREST were not reported because of too small numbers to get
meaningful results.
Sensitivity analysis angiotensin-
converting enzyme inhibitors in relation
to shockable rhythm
In both registries, we found no increased odds of non-shockable
rhythm upon use of ACE inhibitors (Supplementary material online,
Figure S3).
Discussion
In this observational study using real-world data from two indepen-
dent population-based OHCA-registries, we found that use of
non-selective beta-blockers, but not b1-selective beta-blockers, was
associated with non-shockable rhythm. The use of a-b dual receptor
blocker was significantly associated with non-shockable rhythm in
DANCAR—albeit to a lesser extent than non-selective beta-block-
ers—and not significantly in ARREST.
Previous studies have investigated the association between use of
beta-blockers and first-registered heart rhythm in OHCA patients,
but obtained conflicting results.6–9,15 In one single-centre study, a
five-fold increased likelihood of presenting with PEA in patients
treated with beta-blockers was observed.6 The authors hypothesized
that the attenuation of the compensatory catecholaminergic vaso-
constriction in the setting of myocardial dysfunction due to an acute
coronary occlusion could result in circulatory collapse and a low
blood pressure characteristic of PEA; this effect may be more plausi-
ble in case of non-selective drugs with concomitant a-blockade.6
However, the small number of cases included in the study (N = 179)
and the high number of cases excluded due to unknown beta-
blocker status (25%) limit the reliability of these results. Conversely,
another study with a larger cohort including 8266 OHCAs found that
use of beta-blockers was not associated with an increased risk of
non-shockable heart rhythm.7 The fact that this study only investi-
gated the overall effect of beta-blockers on first-registered heart
rhythm without distinguishing among the different classes may
explain why those results differed from ours. While we observed an
association of non-shockable rhythm with the overall use of
beta-blockers in the larger DANCAR registry (but not in the
ARREST registry), this association was modest, and mainly driven by
non-selective beta-blockers. In neither registry did we find an associa-
tion of non-shockable rhythm with b1-selective beta-blockers, which
represent almost 85% of the prescribed beta-blockers in ARREST.
The classes of beta-blockers differ substantially between each
other in several important pharmacodynamic and pharmacokinetic
properties, particularly their affinity and selectivity for the distinct
adrenoceptors.16 Correspondingly, they have distinct clinical indica-
tions.17 Hence, the observed association of non-selective beta-block-
ers with non-shockable rhythm may, in addition to their
pharmacological effect, be related to the underlying disease for which
these drugs are prescribed, e.g. prevention of variceal haemorrhage
in patients with liver disease, which is independently related to non-
shockable rhythm.9 Nonetheless, non-selective beta-blockers
remained significantly associated with non-shockable rhythm when
comorbidities were taken into account.
Similarly, we found that patients taking b1-selective beta-blockers
had a high burden of cardiac diseases such as IHD and CHF or were
treated with digoxin or class I and III antiarrhythmic drugs. All these
conditions have been related to shockable rhythm, and hence they
may have masked the association with non-shockable rhythm.9,18
Accordingly, we did not observe an association with non-shockable
rhythm for sotalol, which is classified as non-selective beta-blocker
according to the ATC classification and is used as an antiarrhythmic
drug in cardiac patients. Besides, due to our study design, we lacked
information about important clinical features, such as left ventricular
ejection fraction. Therefore, we cannot exclude that confounding by
indication or unmeasured confounders have driven our results. To
try to address these issues, we conducted subgroup analyses only in-
cluding patients with similar baseline characteristics which are known
to influence the use of beta-blockers and the first-registered rhythm
in OHCA such as IHD and CHF,4,9,18 and in patients without baseline
cardiovascular comorbidities. Our main results were confirmed in
these subgroup analyses. Thus, we found no evidence that differences
in patient profiles accounted for differential effects on first-registered
heart rhythm upon use of beta-blockers.
It may be also highlighted that animal studies have demonstrated
that pre-arrest therapy with various types of beta-blockers have dif-
ferent effects on the characteristics of the first-registered heart
rhythm and the probability of achieving return of spontaneous circu-
lation.15,19 For instance, some non-selective beta-blockers such as ti-
molol and propranolol were found to have a higher beta-blockade
potency and a larger antifibrillatory potency compared with other
type of beta-blockers.20 Similarly, in the analyses stratified by the dos-
age, we observed a trend towards increasing odds of non-shockable
rhythm with increasing dosage only for non-selective drugs, suggest-
ing a causal relationship.
Whatever the mechanism, it must be emphasized that beta-
blockers remain among the very few drugs that reduce the incidence
of VT/VF because of their antiarrhythmic and antifibrillatory proper-
ties. Thus, use of beta-blockers remains favourable because it is likely
to prevent the occurrence of VT/VF and OHCA in the first place in
many patients, although patients who still experience OHCA while
on beta-blockers are more likely to have non-shockable rhythm.
Considering the importance of the first-registered heart rhythm
during resuscitation attempts and its influence on post-resuscitation
management,10 future studies are required to shed light on the physi-
ological mechanisms which link non-selective beta-blockers to non-
shockable rhythm.
Strengths and limitations
A major strength is that DANCAR and ARREST are specifically
designed to study the incidence, outcomes and determinants of
OHCA, which allows accurate data collection from every OHCA pa-
tient. Also, the population-based design minimized selection bias by
prospectively including every OHCA, rendering our findings repre-
sentative for the community at large. The main limitation is inherent
to the observational nature of our study, i.e. we could only detect
associations, and conclusions on causality should be made with cau-
tion. As previously discussed, confounding by indication may have
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driven our results. Nevertheless, when we repeated the analysis for
ACE inhibitors, which have similar indications as beta-blockers and
whose users had similar differences in baseline characteristics com-
pared with non-users, we did not find an association with any type of
first-registered heart rhythm, rendering it unlikely that residual con-
founding alone may have driven our results.
In both registries, the time to rhythm analysis by EMS was only an
estimate, which may be particularly inaccurate in case of unwitnessed
OHCAs. However, restricting the analyses to witnessed OHCAs
with estimated time to rhythm analysis <_10 min did not alter the
results.
Another limitation is that data on pre-existing disease were missing
in 7.6% of all OHCA patients from ARREST, but the missing data
were distributed proportionally between users and non-users of
beta-blockers. Furthermore, in both registries, we did not have infor-
mation about the therapeutic indication for the use of beta-blockers.
Lastly, it should be acknowledged that the association between non-
selective beta-blockers and PEA was barely significant (lower 95% CI
is 1.01) in the ARREST registry.
Conclusions
Non-selective beta-blockers, but not b1-selective beta-blockers, are
associated with non-shockable rhythm in OHCA.
Supplementary material
Supplementary material is available at Europace online.
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Left bundle branch pacing in a patient with mirror image dextrocardia and
persistent right superior vena cava
Hui-Qiang Wei, Hui Li, Yumei Xue, Shulin Wu, and Xianhong Fang*
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, China
* Corresponding author. Tel: 18613710608335. E-mail address: drfangxh@163.com
An 80-year-old female presented with sympto-
matic bradycardia and mirror image dextrocar-
dia. Vascular access was initiated via the right
axillary vein, a common site for such a proce-
dure. However, it was noted that the initial
guidewire did not take the anticipated course
across the mid-line but instead repeatedly
coursed caudally on the right side of the media-
stinum. Angiography via the right axillary vein
revealed the presence of persistent right supe-
rior vena cava (PRSVC). The complex anatomi-
cal structure posed great challenge for
pacemaker implantation. The left axillary vein
was obtained and the guidewire was successfully
passed through the inferior vena cava. The deliv-
ery sheath was reshaped to reverse-curved
position. The pacing lead was successfully placed
in the left bundle branch area, and left bundle
branch potential was recorded with a low cap-
ture threshold of 0.5 V/0.5 ms (Panel B). Left
bundle branch pacing could be successfully
accomplished in the setting of mirror image
dextrocardia and PRSVC (Panel D).
The full-length version of this report can be
viewed at: https://www.escardio.org/Education/
E-Learning/Clinical-cases/Electrophysiology.
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